NCT01422850View on ClinicalTrials.gov

Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

October 31, 2012

Conditions
Hormone-refractory Prostate Cancer
Interventions
BIOLOGICAL

ALECSAT

Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.

Trial Locations (1)

DK-3600

Department of Urology, Frederikssund

All Listed Sponsors
lead

CytoVac A/S

INDUSTRY

NCT01422850 - Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy | Biotech Hunter | Biotech Hunter